Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2018
Business Overview: CorMedix is a biopharmaceutical company focused on developing Neutrolin, a catheter lock solution designed to prevent infections and thrombosis in patients with central venous catheters (hemodialysis, oncology, critical care). Neutrolin holds CE Mark approval in Europe and the Middle East but is not yet approved by the U.S. FDA. The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $430,000 | $329,000 |
| Cost of Sales | $397,000 | $115,000 |
| Gross Profit | $33,000 | $214,000 |
| Net Loss | $(26.8) million | $(33.0) million |
| Accumulated Deficit | $(179.0) million | $(152.2) million |
| Cash and Cash Equivalents | $17.6 million | $10.4 million |
| Short-Term Investments | $0 | $1.6 million |
| Total Liabilities | $13.9 million | $6.3 million |
| Stockholders' Equity | $4.9 million | $7.2 million |
Note: The filing text does not provide a specific "Cash Flow from Operations" line item in the summary tables, but the MD&A states net cash used in operating activities was $23.7 million for 2018.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31% to $430,000, driven by higher sales in the Middle East and Germany, partially offset by decreased sales in other EU regions.
- Gross Margin Compression: Gross profit decreased 85% to $33,000. This was primarily due to the recognition of additional cost of goods sold related to warranty replacements and the absence of a $327,000 inventory reserve reduction recorded in 2017.
- Reduced Net Loss: Net loss improved by 19% (from $33.0M to $26.8M). This was driven by a $5.7 million decrease in R&D expenses, largely due to a settlement agreement with a Contract Research Organization (CRO) regarding the LOCK-IT-100 clinical trial.
- Debt Issuance: In December 2018, the company issued a $7.5 million senior secured convertible note to a related party (Elliott Associates), increasing total liabilities significantly compared to 2017.
Guidance, Outlook, and Risks
Clinical and Regulatory Outlook
- LOCK-IT-100 Trial: The Phase 3 clinical trial in hemodialysis patients was terminated early in July 2018 after the Data Safety Monitoring Board (DSMB) confirmed statistical significance and efficacy. Topline results announced in January 2019 showed a 71% reduction in catheter-related bloodstream infections (CRBSI) compared to heparin.
- FDA Strategy: The company is in discussions with the FDA regarding the New Drug Application (NDA). While two pivotal trials are generally required, CorMedix is seeking approval based on the single LOCK-IT-100 study, potentially under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). There is no assurance the FDA will not require a second trial.
- International: Neutrolin is commercially available in certain EU and Middle Eastern countries. The company is pursuing regulatory approvals in South Korea and other markets.
Liquidity and Capital Resources
- Cash Runway: Management believes existing cash ($17.6M) plus funds raised through March 8, 2019, will fund operations into the second quarter of 2020.
- Financing Needs: Additional capital is required for a potential second Phase 3 trial, NDA preparation, and commercialization. The company has an At-The-Market (ATM) program and a shelf registration available.
- Reverse Stock Split: A 1-for-5 reverse stock split was approved and scheduled to become effective on March 26, 2019, to meet listing standards.
Key Risks and Contingencies
- Patent Litigation: Ongoing patent infringement proceedings in Germany against TauroPharm regarding the "Prosl European Patent." The European Patent Office (EPO) issued a preliminary decision in November 2017 to invalidate the patent, which CorMedix has appealed. An unfair competition lawsuit was dismissed in December 2018, but CorMedix has appealed that decision as well.
- Regulatory Approval: Failure to obtain FDA approval or the requirement of a second clinical trial would significantly delay commercialization and increase costs.
- Reimbursement: Success depends on obtaining reimbursement from Medicare and private payors, which is not guaranteed.
- Listing Standards: The company received a notice from NYSE American in 2018 regarding non-compliance with stockholders' equity requirements due to sustained losses. A compliance plan was accepted, but failure to regain compliance by December 2019 could result in delisting.
Investor Verification Checklist
- FDA Communication Status: Verify the outcome of discussions with the FDA regarding the NDA submission based on a single trial versus the requirement for a second Phase 3 study.
- Patent Validity: Monitor the status of the appeal regarding the Prosl European Patent (EP 1 814 562 B1) and the unfair competition appeal in Germany, as these are critical to protecting the European market.
- Cash Burn Rate: Confirm the actual cash runway given the high cost of potential additional clinical trials and the timeline for the second quarter of 2020.
- Reverse Stock Split Impact: Assess the impact of the 1-for-5 reverse stock split on liquidity and market perception.
- Debt Covenants: Review the terms of the $7.5 million convertible note, specifically the conversion price ($1.50) and the restrictions on issuing new equity at lower prices due to the backstop agreement with Elliott Associates.